References

The treatment of malignant tumors by repeated inoculations of erysipelas: with a report of ten original cases

10.1097/00003086-199101000-00002 · 1991 · External reference

Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes

10.1126/science.1076514 · 2002 · External reference

Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial

10.1016/s0140-6736(16)00561-4 · 2016 · External reference

Pembrolizumab versus ipilimumab in advanced melanoma

10.1056/nejmoa1503093 · 2015 · External reference

Oncology meets immunology: the cancer-immunity cycle

10.1016/j.immuni.2013.07.012 · 2013 · External reference

Nanoparticulate immunotherapy for cancer

10.1016/j.jconrel.2015.09.062 · 2015 · External reference

Targeting CXCL12 from FAP-expressing carcinoma-associated fibroblasts synergizes with anti-PD-L1 immunotherapy in pancreatic cancer

10.1073/pnas.1320318110 · 2013 · External reference

Regulatory circuits of T cell function in cancer

10.1038/nri.2016.80 · 2016 · External reference

The role of myeloid cells in cancer therapies

10.1038/nrc.2016.54 · 2016 · External reference

Immune cell promotion of metastasis

10.1038/nri3789 · 2015 · External reference

Chemokine nitration prevents intratumoral infiltration of antigen-specific T cells

10.1084/jem.20101956 · 2011 · External reference

Adjuvants that improve the ratio of antigen-specific effector to regulatory T cells enhance tumor immunity

10.1158/0008-5472.can-13-0875 · 2013 · External reference

Cancer immunotherapy comes of age

10.1038/nature10673 · 2011 · External reference

Neutralizing tumor-promoting chronic inflammation: a magic bullet

10.1126/science.1232227 · 2013 · External reference

Targeting myeloid cells using nanoparticles to improve cancer immunotherapy

10.1016/j.addr.2014.09.007 · 2015 · External reference

Engineering synthetic vaccines using cues from natural immunity

10.1038/nmat3775 · 2013 · External reference

Vaccine delivery: a matter of size, geometry, kinetics and molecular patterns

10.1038/nri2868 · 2010 · External reference

Synthetic nanovaccines for immunotherapy

10.1016/j.jconrel.2017.03.033 · 2017 · External reference

Exploiting lymphatic transport and complement activation in nanoparticle vaccines

10.1038/nbt1332 · 2007 · External reference

In vivo targeting of dendritic cells in lymph nodes with poly(propylene sulfide) nanoparticles

10.1016/j.jconrel.2006.01.006 · 2006 · External reference

Nanoparticle conjugation of CpG enhances adjuvancy for cellular immunity and memory recall at low dose

10.1073/pnas.1313152110 · 2013 · External reference

Nanoparticles target distinct dendritic cell populations according to their size

10.1002/eji.200737984 · 2008 · External reference

Engineered materials for cancer immunotherapy

10.1016/j.nantod.2015.06.007 · 2015 · External reference

Targeting nanoparticles to CD40, DEC-205 or CD11c molecules on dendritic cells for efficient CD8(+) T cell response: a comparative study

10.1016/j.jconrel.2014.07.040 · 2014 · External reference

CD40-targeted dendritic cell delivery of PLGA-nanoparticle vaccines induce potent anti-tumor responses

10.1016/j.biomaterials.2014.10.053 · 2015 · External reference

Role of sustained antigen release from nanoparticle vaccines in shaping the T cell memory phenotype

10.1016/j.biomaterials.2012.03.041 · 2012 · External reference

Coencapsulation of tumor lysate and CpG-ODN in PLGA-microspheres enables successful immunotherapy of prostate carcinoma in TRAMP mice

10.1016/j.jconrel.2012.06.015 · 2012 · External reference

Induction of anti-tumor cytotoxic T cell responses through PLGA-nanoparticle mediated antigen delivery

10.1016/j.biomaterials.2011.01.067 · 2011 · External reference

Injectable, spontaneously assembling, inorganic scaffolds modulate immune cells in vivo and increase vaccine efficacy

10.1038/nbt.3071 · 2015 · External reference

Antigen delivery to dendritic cells by poly(propylene sulfide) nanoparticles with disulfide conjugated peptides: cross-presentation and T cell activation

10.1016/j.vaccine.2010.09.077 · 2010 · External reference

pH-Responsive nanoparticle vaccines for dual-delivery of antigens and immunostimulatory oligonucleotides

10.1021/nn305466z · 2013 · External reference

Structure-based programming of lymph-node targeting in molecular vaccines

10.1038/nature12978 · 2014 · External reference

Immune system targeting by biodegradable nanoparticles for cancer vaccines

10.1016/j.jconrel.2013.03.010 · 2013 · External reference

Infection-mimicking materials to program dendritic cells in situ

10.1038/nmat2357 · 2009 · External reference

Nanoparticle-Based Manipulation of antigen-presenting cells for cancer immunotherapy

10.1002/smll.201501284 · 2015 · External reference

Cancer cell membrane-coated nanoparticles for anticancer vaccination and drug delivery

10.1021/nl500618u · 2014 · External reference

Adjuvant-loaded subcellular vesicles derived from disrupted cancer cells for cancer vaccination

10.1002/smll.201600061 · 2016 · External reference

Plasma membrane vesicles decorated with glycolipid-anchored antigens and adjuvants via protein transfer as an antigen delivery platform for inhibition of tumor growth

10.1016/j.biomaterials.2015.09.031 · 2016 · External reference

Designer vaccine nanodiscs for personalized cancer immunotherapy

10.1038/nmat4822 · 2017 · External reference

Immunization with a poly (lactide co-glycolide) encapsulated plasmid DNA expressing antigenic regions of HPV 16 and 18 results in an increase in the precursor frequency of T cells that respond to epitopes from HPV 16, 18, 6 and 11

10.1016/j.cellimm.2011.04.005 · 2011 · External reference

Polymeric materials for gene delivery and DNA vaccination

10.1002/adma.200801478 · 2009 · External reference

A long-lasting dendritic cell DNA vaccination system using lysinylated amphiphiles with mannose-mimicking head-groups

10.1016/j.biomaterials.2012.05.006 · 2012 · External reference

Graphene as cancer theranostic tool: progress and future challenges

10.7150/thno.11387 · 2015 · External reference

Nanoparticulate STING agonists are potent lymph node-targeted vaccine adjuvants

10.1172/jci79915 · 2015 · External reference

Efficient nanovaccine delivery in cancer immunotherapy

10.1021/acsnano.7b00978 · 2017 · External reference

Synthetic nanoparticles for vaccines and immunotherapy

10.1021/acs.chemrev.5b00109 · 2015 · External reference

Polyelectrolyte multilayers assembled entirely from immune signals on gold nanoparticle templates promote antigen-specific T cell response

10.1021/acsnano.5b02153 · 2015 · External reference

Nanoparticle drug delivery systems designed to improve cancer vaccines and immunotherapy

10.3390/vaccines3030662 · 2015 · External reference

The effect of the physical form of poly(lactic-co-glycolic acid) carriers on the humoral immune response to co-delivered antigen

10.1016/j.biomaterials.2004.08.023 · 2005 · External reference

Acetalated dextran is a chemically and biologically tunable material for particulate immunotherapy

10.1073/pnas.0901592106 · 2009 · External reference

Immunological responses triggered by photothermal therapy with carbon nanotubes in combination with anti-CTLA-4 therapy to inhibit cancer metastasis

10.1002/adma.201402996 · 2014 · External reference

Polypyrrole composite nanoparticles with morphology-dependent photothermal effect and immunological responses

10.1002/smll.201503319 · 2016 · External reference

Ultrasmall nanoparticles induce ferroptosis in nutrient-deprived cancer cells and suppress tumour growth

10.1038/nnano.2016.164 · 2016 · External reference

Iron oxide nanoparticles inhibit tumour growth by inducing pro-inflammatory macrophage polarization in tumour tissues

10.1038/nnano.2016.168 · 2016 · External reference

Nanomedicine: an iron age for cancer therapy

10.1038/nnano.2016.199 · 2016 · External reference

Alpha-alumina nanoparticles induce efficient autophagy-dependent cross-presentation and potent antitumour response

10.1038/nnano.2011.153 · 2011 · External reference

A STING-activating nanovaccine for cancer immunotherapy

10.1038/nnano.2017.52 · 2017 · External reference

Microenvironmental regulation of tumor progression and metastasis

10.1038/nm.3394 · 2013 · External reference

Multifunctional plasmonic shell-magnetic core nanoparticles for targeted diagnostics, isolation, and photothermal destruction of tumor cells

10.1021/nn2045246 · 2012 · External reference

Targeted therapeutic remodeling of the tumor microenvironment improves an HER-2 DNA vaccine and prevents recurrence in a murine breast cancer model

10.1158/0008-5472.can-11-1264 · 2011 · External reference

Bioresponsive mesoporous silica nanoparticles for triggered drug release

10.1021/ja206998x · 2011 · External reference

Bimodal tumor-targeting from microenvironment responsive hyaluronan layer-by-layer (LbL) nanoparticles

10.1021/nn502861t · 2014 · External reference

Nanoparticle design to induce tumor immunity and challenge the suppressive tumor microenvironment

10.1016/j.nantod.2014.10.001 · 2014 · External reference

Transforming growth factor-beta and the immune response: implications for anticancer therapy

10.1158/1078-0432.ccr-07-1157 · 2007 · External reference

Combination delivery of TGF-β inhibitor and IL-2 by nanoscale liposomal polymeric gels enhances tumour immunotherapy

10.1038/nmat3355 · 2012 · External reference

How regulatory T cells work

10.1038/nri2343 · 2008 · External reference

The immune contexture in human tumours: impact on clinical outcome

10.1038/nrc3245 · 2012 · External reference

CTLA-4 blockade increases IFNgamma-producing CD4+ICOShi cells to shift the ratio of effector to regulatory T cells in cancer patients

10.1073/pnas.0806075105 · 2008 · External reference

In vivo targeting of intratumor regulatory T cells using PEG-modified single-walled carbon nanotubes

10.1021/bc400070q · 2013 · External reference

Tumor cells and tumor-associated macrophages: secreted proteins as potential targets for therapy

10.1155/2011/565187 · 2011 · External reference

Targeting of tumor-associated macrophages made possible by PEG-sheddable, mannose-modified nanoparticles

10.1021/mp400216r · 2013 · External reference

Targeted delivery of proapoptotic peptides to tumor-associated macrophages improves survival

10.1073/pnas.1312197110 · 2013 · External reference

Efficient identification of murine M2 macrophage peptide targeting ligands by phage display and next-generation sequencing

10.1021/acs.bioconjchem.5b00344 · 2015 · External reference

Molecular-targeted immunotherapeutic strategy for melanoma via dual-targeting nanoparticles delivering small interfering RNA to tumor-associated macrophages

10.1021/acsnano.7b05465 · 2017 · External reference

Local release of highly loaded antibodies from functionalized nanoporous support for cancer immunotherapy

10.1021/ja102414t · 2010 · External reference

In situ activation of platelets with checkpoint inhibitors for post-surgical cancer immunotherapy

10.1038/s41551-016-0011 · 2017 · External reference

Ovarian cancer immunotherapy using PD-L1 siRNA targeted delivery from folic acid-functionalized polyethylenimine: strategies to enhance T cell killing

10.1002/adhm.201500089 · 2015 · External reference

In situ programming of leukaemia-specific T cells using synthetic DNA nanocarriers

10.1038/nnano.2017.57 · 2017 · External reference

Multivalent bi-specific nanobioconjugate engager for targeted cancer immunotherapy

10.1038/nnano.2017.69 · 2017 · External reference

Myeloid-derived suppressor cells: critical cells driving immune suppression in the tumor microenvironment

10.1016/bs.acr.2015.04.002 · 2015 · External reference

Synergy between T-cell immunity and inhibition of paracrine stimulation causes tumor rejection

10.1073/pnas.92.14.6254 · 1995 · External reference

6-Thioguanine-loaded polymeric micelles deplete myeloid-derived suppressor cells and enhance the efficacy of T cell immunotherapy in tumor-bearing mice

10.1007/s00262-015-1702-8 · 2015 · External reference

Magnetic field-induced T cell receptor clustering by nanoparticles enhances T cell activation and stimulates antitumor activity

10.1021/nn405520d · 2014 · External reference

A carbon nanotube-polymer composite for T-cell therapy

10.1038/nnano.2014.154 · 2014 · External reference

Biodegradable nanoellipsoidal artificial antigen presenting cells for antigen specific T-cell activation

10.1002/smll.201402369 · 2015 · External reference

A comprehensive platform for ex vivo T-cell expansion based on biodegradable polymeric artificial antigen-presenting cells

10.1038/mt.2008.11 · 2008 · External reference

Nanoscale artificial antigen presenting cells for T cell immunotherapy

10.1016/j.nano.2013.06.015 · 2014 · External reference

Combination cancer therapies with immune checkpoint blockade: convergence on interferon signaling

10.1016/j.cell.2016.03.031 · 2016 · External reference

Neoadjuvant chemotherapy modulates the immune microenvironment in metastases of tubo-ovarian high-grade serous carcinoma

10.1158/1078-0432.ccr-15-2657 · 2016 · External reference

Eradication of large established tumors in mice by combination immunotherapy that engages innate and adaptive immune responses

10.1038/nm.4200 · 2016 · External reference

Photothermal therapy with immune-adjuvant nanoparticles together with checkpoint blockade for effective cancer immunotherapy

10.1038/ncomms13193 · 2016 · External reference

Combinatorial photothermal and immuno cancer therapy using chitosan-coated hollow copper sulfide nanoparticles

10.1021/nn5002112 · 2014 · External reference

Near-infrared-triggered photodynamic therapy with multitasking upconversion nanoparticles in combination with checkpoint blockade for immunotherapy of colorectal cancer

10.1021/acsnano.7b00715 · 2017 · External reference

Core-shell nanoscale coordination polymers combine chemotherapy and photodynamic therapy to potentiate checkpoint blockade cancer immunotherapy

10.1038/ncomms12499 · 2016 · External reference

Radiotherapy and immunotherapy: a beneficial liaison?

10.1038/nrclinonc.2016.211 · 2017 · External reference

Radiation and checkpoint blockade immunotherapy: radiosensitisation and potential mechanisms of synergy

10.1016/s1470-2045(15)00007-8 · 2015 · External reference

Antigen-capturing nanoparticles improve the abscopal effect and cancer immunotherapy

10.1038/nnano.2017.113 · 2017 · External reference

Therapeutic immunization and local low-dose tumor irradiation, a reinforcing combination

10.1002/ijc.28418 · 2014 · External reference

Human cytotoxic T-lymphocyte membrane-camouflaged nanoparticles combined with low-dose irradiation: a new approach to enhance drug targeting in gastric cancer

10.2147/ijn.s126016 · 2017 · External reference

Immunoengineering: how nanotechnology can enhance cancer immunotherapy

10.1016/j.cell.2015.03.037 · 2015 · External reference